Project Grant R21CA294038
Award Date
12/19/24
Completion Date
11/30/26
Dollars Obligated
$196K
Federal Agency
National Cancer Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
West Haven, CT 06516, USA
Similar Awards
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to harness B cells after stem cell transplant to produce novel chimeric antigen receptor T-cells (CAR-Ts) for treating hematological malignancies. The $415,257 award to Duke University, a leading research institution, will fund research to clone antibody-producing B cells with tumor-binding potential after hematopoietic stem cell transplantation. The goal is to engineer less toxic and...
This federal Project Grant award of $207,900 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health" program supports research at The Leland Stanford Junior University (Stanford University) to develop a three-cell synthetic immunotherapy system. The goal is to engineer T cells, natural killer (NK) cells, and macrophages to express chimeric antigen...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $176,040 to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027. The project aims to develop new strategies to engineer CAR-T cell therapies that can overcome the cancer cell glycocalyx barrier for improved immunotherapy, particularly for solid tumors like breast cancer and glioblastoma. Key objectives include...
This $107,948 Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will fund the development of tunable, microenvironment-responsive CAR T cells to enhance the potency and safety of solid tumor CAR T cell therapy, with a focus on ovarian cancer. The research aims to engineer a hypoxia biosensor circuit in primary human T cells to enable targeted CAR expression and cytokine delivery within the tumor microenvironment, thereby improving anti-tumor efficacy...
The New York University (NYU) School of Medicine was awarded a $1,525,500 Project Grant by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant funding, which runs from September 1, 2024 to August 31, 2027, supports the development of new technologies to address two major bottlenecks in the chimeric antigen receptor (CAR) T cell therapy development process: identifying tumor-specific antigens and engineering...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
The federal Project Grant award of $4,029,612 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the "INFLUENCE TRIAL: IMPROVING EVENT-FREE SURVIVAL BY OPTIMIZING FLUDARABINE EXPOSURE DURING LYMPHODEPLETION FOR CAR T CELL THERAPY" at the Sloan-Kettering Institute for Cancer Research in New York. This grant aims to optimize fludarabine exposure during lymphodepletion to improve event-free survival for patients receiving CAR T-cell...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $627,272 project grant to The Johns Hopkins University on Feb 24, 2025 to develop and optimize engineered, self-propelled tumor-infiltrating CAR T cells using synthetic cytokine receptors (velocity receptors) to enhance their migration speed and tumor infiltration capabilities. The goal is to improve the efficacy of CAR T cell therapy for treating pancreatic cancer, which has a 5-year survival rate of just ~12%....